Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Innoviva Inc (INVA)

Innoviva Inc (INVA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
17.39 unch (unch) 03/14/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 17.39 unch (unch) 16:03 ET
Quote Overview for Fri, Mar 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
17.31
Day High
17.52
Open 17.38
Previous Close 17.39 17.39
Volume 972,500 972,500
Avg Vol 925,685 925,685
Stochastic %K 18.04% 18.04%
Weighted Alpha +9.51 +9.51
5-Day Change -0.25 (-1.42%) -0.25 (-1.42%)
52-Week Range 14.32 - 21.28 14.32 - 21.28
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,089,936
  • Shares Outstanding, K 62,676
  • Annual Sales, $ 358,710 K
  • Annual Income, $ 23,390 K
  • EBIT $ 193 M
  • EBITDA $ 235 M
  • 60-Month Beta 0.56
  • Price/Sales 3.04
  • Price/Cash Flow 5.08
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 51.75% ( -22.12%)
  • Historical Volatility 13.35%
  • IV Percentile 64%
  • IV Rank 37.35%
  • IV High 115.62% on 07/03/24
  • IV Low 13.67% on 06/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 759
  • Open Int (30-Day) 827

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.46
  • Growth Rate Est. (year over year) +217,073.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.00 +2.26%
on 03/13/25
Period Open: 18.08
18.57 -6.35%
on 02/27/25
-0.69 (-3.82%)
since 02/14/25
3-Month
17.00 +2.26%
on 03/13/25
Period Open: 18.58
19.39 -10.29%
on 01/27/25
-1.19 (-6.40%)
since 12/13/24
52-Week
14.32 +21.40%
on 04/16/24
Period Open: 14.72
21.28 -18.28%
on 11/12/24
+2.67 (+18.14%)
since 03/14/24

Most Recent Stories

More News
Innoviva: Q4 Earnings Snapshot

Innoviva: Q4 Earnings Snapshot

INVA : 17.39 (unch)
Innoviva: Q3 Earnings Snapshot

Innoviva: Q3 Earnings Snapshot

INVA : 17.39 (unch)
Innoviva: Q2 Earnings Snapshot

Innoviva: Q2 Earnings Snapshot

INVA : 17.39 (unch)
Innoviva: Q1 Earnings Snapshot

Innoviva: Q1 Earnings Snapshot

INVA : 17.39 (unch)
Innoviva: Q4 Earnings Snapshot

Innoviva: Q4 Earnings Snapshot

INVA : 17.39 (unch)
Chart of the Day: Innoviva - Individual Investor Favorite

The Chart of the Day belongs to the biopharma company Innoviva (INVA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest...

INVA : 17.39 (unch)
Innoviva: Q3 Earnings Snapshot

Innoviva: Q3 Earnings Snapshot

INVA : 17.39 (unch)
Innoviva: Q2 Earnings Snapshot

Innoviva: Q2 Earnings Snapshot

INVA : 17.39 (unch)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

INVA : 17.39 (unch)
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific...

INVA : 17.39 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance,...

See More

Key Turning Points

3rd Resistance Point 17.71
2nd Resistance Point 17.62
1st Resistance Point 17.50
Last Price 17.39
1st Support Level 17.29
2nd Support Level 17.19
3rd Support Level 17.08

See More

52-Week High 21.28
Fibonacci 61.8% 18.62
Fibonacci 50% 17.80
Last Price 17.39
Fibonacci 38.2% 16.98
52-Week Low 14.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals